NovoMatrix in Gingival Recession Coverage: Case Series
Safety and Efficacy of NovoMatrix in Gingival Recession Coverage /A Pilot Clinical and Histological Case Series/
1 other identifier
interventional
20
1 country
1
Brief Summary
Twenty patients seeking treatment for gingival recession coverage, ranging from 20-70 years of age with multiple Miller Class I or II buccal gingival recessions (depth≥3 mm, at least 3 adjacent teeth) will be recruited for this study. Five patients within the study patient pool looking for further orthodontic or restorative treatment that requires removal of one single rooted tooth within the study site of interest will be selected for histological sample removal. All procedures performed in this study will be executed according to established routine protocols, with the exception of block biopsies of one hopeless tooth per patient (total of 5 patients) at 6 months.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started May 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 5, 2024
CompletedFirst Submitted
Initial submission to the registry
May 9, 2024
CompletedFirst Posted
Study publicly available on registry
May 10, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 15, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 15, 2025
CompletedApril 4, 2025
April 1, 2025
1.6 years
May 9, 2024
April 1, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Histology
histologically evaluate the quality of newly formed soft tissues 6 months following gingival recession coverage utilizing NovoMatrix.
6 months
Secondary Outcomes (8)
Postoperative Blood Perfusion changes
Day 0, 1, 4, 7, 10, 14, Month 1, 3, 6
Recession depth
Baseline, 1, 3, 6 months and 1 year
Recession width
Baseline, 1, 3, 6 months and 1 year
Papilla-Contact point distance
Baseline, 1, 3, 6 months and 1 year
Papilla width
Baseline, 1, 3, 6 months and 1 year
- +3 more secondary outcomes
Study Arms (1)
Coronally Advanced Tunnel with NovoMatrix
EXPERIMENTALGingival Augmentation Procedure using NovoMatrix + Coronally Advanced Tunnel
Interventions
An intrasulcular incision on the tooth with recession and on each adjacent tooth. Subperiosteal pouches dissected apically for about 6-8 mm facial to the 3 teeth and connected by extension of the subperiosteal dissection into the interdental areas to create a tunnel. NovoMatrix trimmed to a vertical dimension of 7-8 mm and a horizontal length to completely over the exposed roots and extend laterally to the root line angles of the adjacent teeth. The graft inserted into the tunnel and aligned. Both the overlying tissue and graft positioned 1mm coronally to the level of the cementoenamel junction and secured with a 6-0 resorbable sling suture.
Eligibility Criteria
You may qualify if:
- Male or female, between 20-70 years of age, who request gingival augmentation or recession coverage.
- Subjects who are willing to sign an informed consent, participate and return for follow-up visits.
- Subjects without significant medical history and currently not on medications that might complicate treatment outcomes.
- Subjects demonstrating good oral hygiene (FMPS, FMBS less than 20%).
You may not qualify if:
- Subjects who received and failed a previously placed autogenous graft.
- Subjects who have significant untreated periodontal disease, caries, infection or chronic inflammation in the oral cavity within two adjacent tooth positions of the clinical trial area.
- Subjects who have used nicotine-containing products within 3 weeks prior to surgery.
- Subjects who are insulin-dependent diabetic or if their Hgb1c levels \> 6.5%.
- Subjects who have had a history of malignancy within the past 5 years (except for basal or squamous cell carcinoma of the skin or in situ cervical carcinoma).
- Subjects who are nursing or pregnant.
- Subjects who are presently taking medications (except estrogen/progesterone therapy) or those who are undergoing treatment that in known to have an effect on bone turnover.
- Subjects who have diseases that affect bone metabolism (excluding idiopathic osteoporosis).
- Subjects with a history of an autoimmune disease, documented allergy or multiple allergies to any component of the agents used in this study.
- Acutely infected mucogingival defect site.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Semmelweis University, Faculty of Dentistry
Budapest, 1088, Hungary
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Péter Windisch, Profesor
Semmelweis University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 9, 2024
First Posted
May 10, 2024
Study Start
May 5, 2024
Primary Completion
December 15, 2025
Study Completion
December 15, 2025
Last Updated
April 4, 2025
Record last verified: 2025-04
Data Sharing
- IPD Sharing
- Will not share